Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Celldex Therapeutics (CLDX) Research & Development (2016 - 2025)

Celldex Therapeutics has reported Research & Development over the past 16 years, most recently at $75.3 million for Q4 2025.

  • Quarterly results put Research & Development at $75.3 million for Q4 2025, up 60.49% from a year ago — trailing twelve months through Dec 2025 was $245.1 million (up 49.85% YoY), and the annual figure for FY2025 was $245.1 million, up 49.85%.
  • Research & Development for Q4 2025 was $75.3 million at Celldex Therapeutics, up from $62.9 million in the prior quarter.
  • Over the last five years, Research & Development for CLDX hit a ceiling of $75.3 million in Q4 2025 and a floor of $12.4 million in Q2 2021.
  • Median Research & Development over the past 5 years was $28.6 million (2023), compared with a mean of $33.1 million.
  • Biggest five-year swings in Research & Development: rose 8.76% in 2021 and later surged 67.78% in 2022.
  • Celldex Therapeutics' Research & Development stood at $14.7 million in 2021, then soared by 56.01% to $22.9 million in 2022, then skyrocketed by 32.87% to $30.4 million in 2023, then skyrocketed by 54.27% to $46.9 million in 2024, then surged by 60.49% to $75.3 million in 2025.
  • The last three reported values for Research & Development were $75.3 million (Q4 2025), $62.9 million (Q3 2025), and $54.2 million (Q2 2025) per Business Quant data.